New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation

American Journal of Health-System Pharmacy

Volumn 67, Issue 9 SUPPL. 5, 2010, Pages

  Cheng, Judy W M ^a,b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amiodarone; Anticoagulants; Atrial fibrillation; Cardiac drugs; Dabigatran; Dosage; Dronedarone; Mechanism of action; Rivaroxaban; Toxicity; Vernakalant; Warfarin

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DABIGATRAN; DRONEDARONE; PLACEBO; RIVAROXABAN; VERNAKALANT; WARFARIN; NEW DRUG;

ABDOMINAL PAIN; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORNEA DISEASE; CORNEAL DEPOSIT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART PROARRHYTHMIA; HEART RHYTHM; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LIVER TOXICITY; LUNG FIBROSIS; NAUSEA; NEUROPATHY; OPTIC NEURITIS; PHOTOSENSITIVITY; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; VOMITING; AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BIOLOGICAL MODEL; CASE REPORT; CATHETER ABLATION; DOSE RESPONSE; HEART ATRIOVENTRICULAR NODE; MALE; METHODOLOGY;

AGED; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; CATHETER ABLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; HUMANS; MALE; MODELS, CARDIOVASCULAR; PACEMAKER, ARTIFICIAL;

EID: 77954902986     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100154     Document Type: Conference Paper

References (30)

1. Multaq package insert. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2009 Jul.
2. U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Multaq (dronedarone) briefing document. March 18, 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM134981.pdf (accessed 2010 Feb 1).
3. U.S. Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Kynapid (vernakalant hydrochloride injection) briefing materials. December 11, 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4327b1- 01-astellas-backgrounder.pdf (accessed 2010 Feb 1).
4. Sanoski CA, Bauman JL, Dekker Schoen M. The arrhythmias. In: Dipiro JT, Talbert RL, Yee GC et al., eds. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York, NY: McGraw-Hill; 2008:279-314.
5. Cheng JW. Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008; 42:533-42. (Pubitemid 351521968)
6. McEvoy GK, ed. Amiodarone hydrochloride. In: AHFS drug information 2010. Bethesda, MD: American Society of Health-System Pharmacists; 2010:1671-85.
7. Singh BN, Connolly SJ, Crijns HJ et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357:987-99. (Pubitemid 47367078)
8. Køber L, Torp-Pedersen C, McMurray JJ et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358:2678-87. (Pubitemid 351860860)
9. Hohnloser SH, Crijns HJ, van Eickels M et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009; 360:668-78.
10. Orth PM, Hesketh JC, Mak CK et al. RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res. 2006; 70:486-96.
11. Fedida D, Orth PM, Chen JY et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005; 16:1227-38.
12. Roy D, Pratt CM, Torp-Pedersen C et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008; 117:1518-25. (Pubitemid 351440640)
13. Stiell I, Roy D, Pratt C et al. RSD1235 effectively converts acute atrial fibrillation to sinus rhythm independent of background use of oral rate- or rhythm-control medications. Ann Emerg Med. 2006; 48:S46. Abstract 148.
14. Kowey PR, Dorian P, Mitchell LB et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009; 2:652-9.
15. Neel S. Essential warfarin knowledge. In: Gulseth M. Managing anticoagulation patients in the hospital. Bethesda, MD: American Society of Health-System Pharmacists; 2007:133-75.
16. Gulseth MP, Michaud J, Nutescu E. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health-Syst Pharm. 2008; 65:1520-9.
17. Johnson & Johnson. FDA issues complete response letter for rivaroxaban. http://www.jnj.com/connect/news/all/20090528-103000 (accessed 2010 Feb 9).
18. Xarelto summary of product characteristics. Berlin, Germany: Bayer Schering Pharma AG; May 2009. http://www.xarelto.com/html/downloads/Xarelto- Summary-of-Product-Characteristics-May2009.pdf (accessed 2010 Feb 9).
19. Francis CW. New issues in oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2008:259-65. http://asheducationbook.hematologylibrary.org/cgi/ content/full/2008/1/259 (accessed 2010 Feb 9).
20. Pradaxa summary of product characteristics. Ingelheim am Rhein, Germany: Boehringer Ingelheim International; March 2009. http://www.pradaxa.com/Include/ media/pdf/Pradaxa-SPC-EMEA.pdf (accessed 2010 Feb 9).
21. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008; 28:1354-73.
22. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
23. Ozcan C, Jahangir A, Friedman PA et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med. 2001; 344:1043-51. (Pubitemid 32267974)
24. Parks R. Catheter ablation for atrial fibrillation. http://www. revolutionhealth.com/articles/catheter-ablation-for-atrial-fibrillation/ hw159948 (accessed 2010 Feb 10).
25. Mayo Foundation for Medical Education and Research. Cardiac catheter ablation. http://www.mayoclinic.org/atrial-fibrillation-ablation/ (accessed 2010 Feb 11).
26. Oral H, Knight BP, Tada H et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation. 2002; 105:1077-81. (Pubitemid 34212617)
27. Koller ML, Schumacher B. Cryoballoon ablation of paroxysmal atrial fibrillation: bigger is better and simpler is better. Eur Heart J. 2009; 30:699-709.
28. Bhatt DL. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation (STOP-AF). www.cardiosource.com/clinicaltrials/trial.asp?trialID= 1922(accessed 2010 March 26).
29. Packer DL et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front Stop-AF clinical trial. Presented at American College of Cardiology 59th Annual Scientific Session. Atlanta, GA: 2010 Mar 15. Abstract 3015-6.
30. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation. 2006; 114:e257-e354. http://circ.ahajournals.org/cgi/content/full/114/7/e257 (accessed 2010 Feb 28).